Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Journal of Hematology & Oncology, 06/12/2012Chen H et al.
The results indicate that relapse rate can be reduced and diseasefree survival (DFS) may be improved in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) patients with imatinib maintenance therapy after HCT. BCR–ABL monitoring by quantitative reverse–transcription polymerase chain reaction (qRT–PCR) can guide maintenance therapy with imatinib including initiation time and treatment duration after allogeneic hematopoietic stem cell transplantation (allo–HCT)
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.